122
Participants
Start Date
May 31, 1991
Primary Completion Date
May 31, 1992
Study Completion Date
August 31, 1992
losartan potassium
losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks
Comparator: placebo
placebo capsules to losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks
hydrochlorothiazide (HCTZ)
open-label hydrochlorothiazide (HCTZ) 12.5 mg (for patients with Sitting Diastolic Blood Pressure (SiDBP) ≥85 mm Hg after 4 weeks of losartan monotherapy (Combination Therapy Period)) orally once daily (q.d.) for 2 weeks
Merck Sharp & Dohme LLC
INDUSTRY